LPL Financial today released its 2026 Outlook: The Policy Engine. Reflecting on the second half of 2025 and looking ahead to the new year, this report offers a comprehensive analysis of the economic ...

The global and European economies have been resilient in recent years even accounting for the modest global slowdown of 2025.

Our 2026 S&P 500 Index target is 8,000 for 2026, assuming a 23x multiple of 2027 estimated S&P earnings of 348. Read more ...

Mike Wolanin | The Republic Phil Powell, executive director of the Indiana Business Research Center and clinical associate professor of business economics and public policy at the Kelley School of ...

People are getting more pessimistic about their own financial outlook for the year ahead, according to the latest Survey of Consumer Expectations from the Federal Reserve Bank of New York. More than a ...

How are financial institutions balancing the competing priorities of needing to get risk management right while simultaneously being under cost-pressure and needing to onboard quickly to ensure a good ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...

LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in ...

The global and European economies have been resilient in recent years even accounting for the modest global slowdown of 2025. But risks for the recovery are rising, underscoring a negative medium-run ...

Join the Puget Sound Business Journal for the 2026 Economic Outlook, where local executives and industry leaders will gather to hear expert predictions and analysis on the economic landscape for the ...

U.S. Food and Drug Administration (FDA) PDUFA goal date for ONS-5010 is August 27, 2025. Off-label repackaged bevacizumab is one of the most frequently used first-line anti-VEGF treatments in Europe ...